The panel agreed that while there is limited evidence for the efficacy of PARPi in HER2-negative metastatic BC patients with tumours harbouring somatic BRCA pathogenic variants, this is in part due to the paucity of studies involving BC patients with deleterious somatic mutations of BRCA1/2 (Statement No. 21). The gene discussed is BRCA1; the disease is neoplasm.